In the Arkansas dataset of patients treated with a bortezomib-based induction regimen, those with a PTPROt expression level higher than the median had a superior overall survival than those whose myeloma cells had a median or lower PTPROt expression (Figure 6A; P = 0.0175). Here, PTPRO is linked to plasma cell myeloma.